Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a Phase II trial in 48 patients already receiving high doses of lipid-lowering drugs, the 2 higher doses of ISIS 301012 met the
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury